Furthermore, treatment of a 27-year-old patient with subacute anti-neurofascin-155 neuropathy with rituximab was associated with an improvement in clinical and neurophysiological parameters and a reduction in antibody titers and LC density25. The gene discussed is NFASC; the disease is neuropathy.